US Cancer Antibody Market, Drug Price, Sales and Clinical Trials Insight 2026

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

For Latest Publication Visit Following Report Weblink

Click Here: US Cancer Antibodies Market, Drug Sales, Patent and Clinical Trials Outlook 2028

"US Cancer Antibody Market, Drug Price, Sales and Clinical Trials Insight 2026" Report Highlights:

US Cancer Antibodies Market Opportunity: > US$ 70 Billion by 2026
US Cancer Antibodies Market Growth: 100% Absolute Growth Till 2026
US Cancer Antibodies Market Size Opportunity by Therapeutic Class
Insight On Clinical Trials by Company, Indication, Patient Segment and Phase
Insight on FDA Approved 57 Cancer Antibodies Available in US Market
Price, Dosage, Patent and Sales Insight on Cancer Antibodies Available In Market
US Cancer Biosimilar Market Opportunity Insight: > US$ 10 Billion by 2026

Over the past few years, there has been a growing race to develop an enhanced version of cancer therapeutics market at global level. To acquire such growing parameters, the US cancer market started intensifying the importance of cancer antibody market by making itself among the top markets to establish compete set of research paradigms important for the respective market. US cancer antibody market has increased the overall market growth rate and size of oncology sector, as the respective market carries the ability to optimize the high-ending demands of the cancer patient population for having a stable and efficient therapy for different cancers. In addition, the extensive development rate of healthcare in the form of diagnosis and drug research and development is estimated to benefit the cancer-antibody drug market enormously when compared with other country’s market.

Cancer antibodies have helped the researchers in leaning the entire cancer therapeutics market towards a great transition i.e. from delivering adverse side effects to receiving tons of healthcare benefits such as no adverse side effects or cancer recurrence. Also, availability of prominent designing and research tools in the US have also helped the scientific researchers to design potent cancer-antibody drugs in terms of functionality, quality, and cost. It can be witnessed for the US cancer antibody drug market that the potential impact of the market on US cancer market is far ahead of the clinical implications observed for large base of chemotherapeutics agents and many more.

The extensive and well established base for oncology sector and specifically cancer-antibody drug market has made the US industry share a big percentage to the global development in this respective market, despite of the fact that there are numerous emerging powers in the world. With excessive use of pharmacoeconomics, relaxed formularies as well as e-prescribing market, high number of payers and healthcare policy-makers are also assessing the market towards boosting the research and development platform of the market by adding monotherapy and bispecific therapy to it.

To an extensive level, it is witnessed that the rising volume of research activities and quality of data available in the country have driven the adoption rate of novel drug approvals and grants for research and development platform related with the market. In addition, the primary regulatory body in the country has also made greater use of fast-track methods for making the entire market boomed with breakthroughs and achievements. In the US, technology advancement is also considered as a democratizing force for boosting the market paradigm for cancer-antibody drug market. Biotech and bio-pharmaceutical companies are also inducing patient-centric approaches for turning simple cancer antibody market to a market full of off-to-strategies. In addition, the total spending of medicines in cancer-antibody drug market is expected to increase, thus leading to the adoption of novel wave for innovative and promising products. Some of the prominent factors that will be driving the US cancer antibody drug market are: pricing shifts and emergence and growth of biosimilars. In the respective research report, reported sales, growing trends and opportunities, challenge for future market has been compared, thus providing a realistic idea for the market.

US Cancer Antibodies Market Analysis

1.1 Overview

1.2 Current Market Scenario

1.3 US - Leading Cancer Antibodies

US Cancer Antibodies Market Segmentation by Therapeutic Class

2.1 Immune Checkpoint Inhibitors

2.2 US Bispecific Antibody Market

2.3 US Antibody Drug Conjugate Market

2.4 Other Cancer Antibody Therapeutics

2.4.1 VEGF/VEGFR Inhibiting Antibodies

2.4.2 CD20 Targeting Antibodies

2.4.3 CD38 Targeting Antibodies

2.4.4 EGFR Inhibiting Antibodies

US Breast Cancer Antibodies Market

3.1 Current Market Scenario

3.2 Leading Breast Cancer Antibodies

US Blood Cancer Antibody Market

4.1 Current Market Scenario

4.2 Leading Blood Cancer Targeting Antibodies

US Lung Cancer Antibody Market

5.1 Current Market Scenario

5.2 Leading Antibodies for Lung Cancer

US Colorectal Cancer Antibodies Market Overview

US Cancer Biosimilar Market

7.1 Current Market Scenario

7.2 Market Opportunity and Future Forecast

Global Peptide Cancer Therapeutics Clinical Trials Overview

8.1 By Company

8.2 By Indication

8.3 By Patient Segment

8.4 By Phase

US HER2 Inhibiting Antibodies - Availability, Dosage, Patent, Price and Sales Analysis

9.1 Trastuzumab (Herceptin)

9.2 Trastuzumab Biosimilar (Ontruzant)

9.3 Trastuzumab Biosimilar (Ogivri)

9.4 Trastuzumab Biosimilar (Herzuma)

9.5 Trastuzumab Biosimilar (Trazimera)

9.6 Trastuzumab Biosimilar (Kanjinti)

9.7 Trastuzumab and Hyaluronidase Injection (Herceptin Hylecta)

9.8 Pertuzumab (Perjeta)

9.9 Margetuximab (Margenza)

US VEGF/VEGFR Inhibiting Antibodies -Availability, Dosage, Patent, Price and Sales Analysis

10.1 Bevacizumab (Avastin)

10.2 Bevacizumab Biosimilar (Mvasi)

10.3 Bevacizumab Biosimilar (Zirabev)

10.4 Ramucirumab (Cyramza)

US Antibody-Drug Conjugates - Availability, Dosage, Patent, Price and Sales Analysis

11.1 Ado-Trastuzumab Emtansine (Kadcyla)

11.2 Fam-Trastuzumab Deruxtecan (Enhertu)

11.3 Trodelvy (Sacituzumab Govitecan-hziy)

11.4 Moxetumomab Pasudotox-tdfk (Lumoxiti)

11.5 Inotuzumab Ozogamicin (Besponsa)

11.6 Gemtuzumab Ozogamicin (Mylotarg)

11.7 Belantamab Mafodotin-blmf (Blenrep)

11.8 Brentuximab Vedotin (Adcetris)

11.9 Polatuzumab Vedotin-piiq (Polivy)

11.10 Enfortumab Vedotin (Padcev)

US CD20-Directed Antibody - Availability, Dosage, Patent, Price and Sales Analysis

12.1 Rituximab (Mabthera/Rituxan)

12.2 Rituximab Biosimilar (Truxima)

12.3 Rituximab Biosimilar (Riabni)

12.4 Rituximab Biosimilar (Ruxience)

12.5 Rituximab/Hyaluronidase (Rituxan Hycela)

12.6 Obinutuzumab (Gazyva)

12.7 Ofatumumab (Arzerra)

US Bispecific Antibodies - Availability, Dosage, Patent, Price and Sales Analysis

13.1 Blinatumomab (Blincyto)

CD52 Monoclonal Antibodies - Availability, Dosage, Patent, Price and Sales Analysis

14.1 Alemtuzumab (Lemtrada)

CD38 Monoclonal Antibodies - Availability, Dosage, Patent, Price and Sales Analysis

15.1 Isatuximab-irfc (Sarclisa)

15.2 Darzalex (Daratumumab)

15.3 Darzalex Faspro (Daratumumab/Hyaluronidase)

Immune Checkpoint Inhibitor - Availability, Dosage, Patent, Price and Sales Analysis

16.1 Pembrolizumab (Keytruda )

16.2 Ipilimumab (Yervoy)

16.3 Nivolumab (Opdivo)

16.4 Durvalumab (Imfinzi) – Urothelial Carcinoma

16.5 Avelumab (Bavencio)

16.6 Atezolizumab (Tecentriq)

16.7 Cemiplimab (Libtayo)

EGFR Inhibitors - Availability, Dosage, Patent, Price and Sales Analysis

17.1 Cetuximab (Erbitux)

17.2 Portrazza (Necitumumab)

17.3 Nimotuzumab

17.4 Panitumumab (Vectibix)

Combinational Antibodies - Availability, Dosage, Price and Sales Analysis

18.1 Trastuzumab, Pertuzumab, and Hyaluronidase (Phesgo)

Others Cancer Targeting Antibodies of US - Availability, Dosage, Patent, Price and Sales Analysis

19.1 Tagraxofusp (Elzonris)

19.2 Tafasitamab (Monjuvi)

19.3 Mogamulizumab-kpkc (Poteligeo)

19.4 Denosumab (Xgeva)

19.5 Empliciti (Elotuzumab)

19.6 Unituxin (dinutuximab) Neuroblastoma

19.7 Satumomab

19.8 Naxitamab-gqgk (Danyelza)

19.9 Iodine I 131 Derlotuximab Biotin

19.10 Capromab Pendetide (ProstaScint)

Competitive Landscape

20.1 Amgen

20.2 AryoGen Pharmed

20.3 AstraZeneca plc

20.4 BIOCAD

20.5 Boehringer Ingelheim

20.6 Bristol Mayer Squibb

20.7 Daiichi Sankyo Company

20.8 Genentech

20.9 Immunomedics

20.10 Innovent Biologics

20.11 Jassen Pharmaceuticals

20.12 MacroGenics

20.13 mAbxience

20.14 Mylan

20.15 Outlook Therapeutics

20.16 Pfizer

20.17 Prestige Biopharma

20.18 Roche

20.19 Samsung Bio

20.20 Seagen

Figure 1-1: US – Estimated Newly Diagnosed Cancer Cases (Million), 2020, 2025 and 2030

Figure 1-2: US – Estimated Cancer Deaths, 2020, 2025 and 2030

Figure 1-3: Global – Cancer Antibody Market Opportunity (US$ Billion), 2020 - 2026

Figure 1-4: Global – Cancer Therapeutics Market Opportunity (US$ Billion), 2020 - 2026

Figure 1-5: US – Keytruda Annual Sales Value (US$ Billion), 2019 and 2020

Figure 1-6: US - Opdivo Annual Sales Value (US$ Billion), 2019 and 2020

Figure 1-7: US - Rituxan Annual Sales Value (US$ Billion), 2019 and 2020

Figure 1-8: US - Darzalex Annual Sales Value (US$ Billion), 2019 and 2020

Figure 1-9: US - Avastin Annual Sales Value (US$ Billion), 2019 and 2020

Figure 1-10: US - Tecentriq Annual Sales Value (US$ Billion), 2019 and 2020

Figure 1-11: US - Perjeta Annual Sales Value (US$ Billion), 2019 and 2020

Figure 1-12: US - Herceptin Annual Sales Value (US$ Billion), 2019 and 2020

Figure 1-13: US - Xgeva Annual Sales Value (US$ Billion), 2019 and 2020

Figure 1-14: US - Imfinzi Annual Sales Value (US$ Billion), 2019 and 2020

Figure 2-1: Major Types of Cancer Targeting Antibodies

Figure 2-2: Global – Immune Checkpoint Inhibitors Market by Region (US$ Billion), 2020

Figure 2-3: Global – Immune Checkpoint Inhibitors Market by Region (%), 2020

Figure 2-4: US – Immune Checkpoint Inhibitors Market Opportunity (US$ Billion), 2020 - 2026

Figure 2-5: Global – Immune Checkpoint Inhibitors Market Opportunity (US$ Billion), 2020 - 2026

Figure 2-6: US – Sales Value of Leading Immune Checkpoint Inhibitors (US$ Billion), 2020

Figure 2-7: US – Immune Checkpoint Inhibitors Market Size by Product (%), 2020

Figure 2-8: Global – Bispecific Antibody Market by Region (US$ Million), 2020

Figure 2-9: Global – Bispecific Antibody Market by Region (%), 2020

Figure 2-10: US – Bispecific Antibody Market (US$ Million), 2016-2020

Figure 2-11: US – Bispecific Antibody Market Opportunity (US$ Million), 2020 - 2026

Figure 2-12: Global – Bispecific Antibody Market Opportunity (US$ Million), 2020 - 2026

Figure 2-13: Global – Antibody Drug Conjugate Market by Region (US$ Million), 2020

Figure 2-14: Global – Antibody Drug Conjugate Inhibitors Market by Region (%), 2020

Figure 2-15: US – Antibody Drug Conjugate Inhibitors Market Opportunity (US$ Million), 2020 - 2026

Figure 2-16: Global – Antibody Drug Conjugate Inhibitors Market Opportunity (US$ Million), 2020 - 2026

Figure 2-17: US – Sales Value of Leading Antibody Drug Conjugates (US$ Million), 2020

Figure 2-18: US – Antibody Drug Conjugate Inhibitors Market Size by Product (%), 2020

Figure 2-19: Global – VEGF/VEGFR Inhibitor Antibody Market by Region (US$ Billion), 2020

Figure 2-20: Global – VEGF/VEGFR Inhibitor Antibody Market by Region (%), 2020

Figure 2-21: US – VEGF/VEGFR Inhibitor Antibody Market Opportunity (US$ Billion), 2020 - 2026

Figure 2-22: Global – VEGF/VEGFR Inhibitor Antibody Market Opportunity (US$ Billion), 2020 - 2026

Figure 2-23: US – Sales Value of Leading VEGF/VEGFR Inhibitor Antibodies (US$ Million), 2020

Figure 2-24: US – CD20 Inhibitor Cancer Antibody Market Opportunity (US$ Billion), 2020 - 2026

Figure 2-25: US – Sales Value of Leading CD20 Inhibitor Cancer Antibody (US$ Million), 2020

Figure 2-26: US – Sales Value of Leading CD20 Inhibitor Cancer Antibody (%), 2020

Figure 2-27: US – CD38 Inhibitor Cancer Antibody Market Opportunity (US$ Billion), 2020 - 2026

Figure 2-28: US – Sales Value of Leading CD38 Inhibitor Cancer Antibody (US$ Billion), 2020

Figure 2-29: US – Sales Value of Leading CD38 Inhibitor Cancer Antibody (%), 2020

Figure 3-1: US – Estimated Newly Diagnosed Breast Cancer Cases, 2020, 2025 and 2030

Figure 3-2: US – Estimated Breast Cancer Deaths, 2020, 2025 and 2030

Figure 3-3: US – Sales of Leading Breast Cancer Antibodies (US$ Billion), 2019

Figure 3-4: US – Sales of Leading Breast Cancer Antibodies (US$ Billion), 2020

Figure 4-1: US – Estimated Newly Diagnosed Blood Cancer Cases by Type, 2020

Figure 4-2: US – Estimated Blood Cancer Deaths by Type, 2020

Figure 4-3: US – Sales of Leading Blood Cancer Antibodies (US$ Billion), 2019

Figure 4-4: US – Sales of Leading Blood Cancer Antibodies (US$ Billion), 2020

Figure 5-1: US – Estimated Newly Diagnosed Lung Cancer Cases, 2020, 2025 and 2030

Figure 5-2: US – Estimated Lung Cancer Deaths, 2020, 2025 and 2030

Figure 5-3: US – Sales of Leading Lung Cancer Antibodies (US$ Billion), 2019

Figure 5-4: US – Sales of Leading Lung Cancer Antibodies (US$ Billion), 2020

Figure 6-1: US – Estimated Newly Diagnosed Colon Cancer Cases, 2020, 2025 and 2030

Figure 6-2: US – Estimated Colon Cancer Deaths, 2020, 2025 and 2030

Figure 6-3: US – Estimated Newly Diagnosed Rectum Cancer Cases, 2020, 2025 and 2030

Figure 6-4: US – Estimated Rectum Cancer Deaths, 2020, 2025 and 2030

Figure 6-5: US – Colorectal Cancer Therapeutics Market Opportunity (US$ Billion), 2020 - 2026

Figure 7-1: US – Average Price for 150mg Branded and Biosimilar Trastuzumab (US$), March’2021

Figure 7-2: US – Average Price for 4ml Branded and Biosimilar Bevacizumab (US$), March’2021

Figure 7-3: US – Average Price for 16ml Branded and Biosimilar Bevacizumab (US$), March’2021

Figure 7-4: US – Average Price for 10ml Branded and Biosimilar Rituximab (US$), March’2021

Figure 7-5: US – Average Price for 50ml Branded and Biosimilar Rituximab (US$), March’2021

Figure 7-6: US – Estimated Patent Expiration Year of Cancer Antibodies

Figure 7-7: US – Cancer Biosimilar Antibody Market Size by Product (US$ Million), 2020

Figure 7-8: US – Cancer Biosimilar Antibody Market Size by Product (%), 2020

Figure 7-9: US – Rituxan Biosimilar Market Size by Product (US$ Million), 2020

Figure 7-10: US – Rituxan Market Size by Product (US$ Million), 2020

Figure 7-11: US – Bevacizumab Biosimilar Market Size by Product (US$ Million), 2020

Figure 7-12: US – Bevacizumab Market Size by Product (%), 2020

Figure 7-13: US – Trastuzumab Biosimilar Market Size by Product (US$ Million), 2020

Figure 7-14: US – Trastuzumab Market Size by Product (%), 2020

Figure 7-15: US – Cancer Biosimilar Antibody Market Opportunity (US$ Billion), 2020 - 2026

Figure 7-16: US – Zirabev Market Opportunity (US$ Million), 2020 - 2026

Figure 7-17: US – Mvasi Market Opportunity (US$ Million), 2020 - 2026

Figure 7-18: US – Rituximab Biosimilar Market Opportunity (US$ Million), 2020 - 2026

Figure 7-19: US – Kanjinti Market Opportunity (US$ Million), 2020 - 2026

Figure 7-20: US – Trastuzumab Biosimilar Market Opportunity (US$ Million), 2020 - 2026

Figure 8-1: US - Cancer Antibodies Clinical Pipeline by Company (Number of Drugs), 2021 till 2026

Figure 8-2: US - Cancer Antibodies Clinical Pipeline by Indication (Number of Drugs), 2021 till 2026

Figure 8-3: US - Cancer Antibodies Clinical Pipeline by Patient Segment (Number of Drugs), 2021 till 2026

Figure 8-4: US - Cancer Antibodies Clinical Pipeline by Phase (Number of Drugs), 2021 till 2026

Figure 9-1: Herceptin – Approval Year by Cancer Type

Figure 9-2: Herceptin – Price for a Supply of 10 and Price for Single 150mg Powder for Injection (US$), March’2021

Figure 9-3: Herceptin – Initial and Maintenance Dose for Breast Cancer Treatment (mg/kg), March’2021

Figure 9-4: Herceptin – Cost of Initial Dose, Maintenance Dose and Annual Treatment Cost of Breast Cancer (US$), March’2021

Figure 9-5: Herceptin – Initial and Maintenance Dose for Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (mg/kg), March’2021

Figure 9-6: Herceptin – Cost of Initial Dose, Maintenance Dose and Annual Treatment Cost of Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (US$), March’2021

Figure 9-7: US - Herceptin Annual Sales Value (US$/CHF Million), 2017 - 2020

Figure 9-8: US - Herceptin Quarterly Sales Value (US$/CHF Million), 2019

Figure 9-9: US - Herceptin Quarterly Sales Value (US$ Billion), 2020

Figure 9-10: Ontruzant – Price for 150mg and 420mg Powder for Injection (US$), March’2021

Figure 9-11: Ontruzant – Initial and Maintenance Dose for Breast Cancer (mg/kg/Week), March’2021

Figure 9-12: Ontruzant – Average Cost of Initial Week, Maintenance Week and Annual (US$), March’2021

Figure 9-13: Ontruzant – Initial and Maintenance Dose for Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (mg/kg), March’2021

Figure 9-14: Ontruzant – Cost of Initial Dose, Maintenance Dose and Annual Treatment Cost of Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (US$), March’2021

Figure 9-15: Ogivri – Price for 150mg and 420mg Powder for Injection (US$), March’2021

Figure 9-16: Ogivri – Initial and Maintenance Dose for Breast Cancer (mg/kg/Week), March’2021

Figure 9-17: Ogivri – Average Cost of Initial Week, Maintenance Week and Annual (US$), March’2021

Figure 9-18: Ogivri – Initial and Maintenance Dose for Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (mg/kg), March’2021

Figure 9-19: Ogivri – Cost of Initial Dose, Maintenance Dose and Annual Treatment Cost of Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (US$), March’2021

Figure 9-20: Herzuma – Price for 150mg and 420mg Powder for Injection (US$), March’2021

Figure 9-21: Herzuma – Initial and Maintenance Dose for Breast Cancer (mg/kg/Week), March’2021

Figure 9-22: Herzuma – Average Cost of Initial Week, Maintenance Week and Annual (US$), March’2021

Figure 9-23: Herzuma – Initial and Maintenance Dose for Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (mg/kg), March’2021

Figure 9-24: Herzuma – Cost of Initial Dose, Maintenance Dose and Annual Treatment Cost of Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (US$), March’2021

Figure 9-25: Trazimera – Initial and Maintenance Dose for Breast Cancer (mg/kg/Week), March’2021

Figure 9-26: Trazimera – Average Cost of Initial Week, Maintenance Week and Annual treatment (US$), March’2021

Figure 9-27: Trazimera – Initial and Maintenance Dose for Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (mg/kg), March’2021

Figure 9-28: Trazimera – Cost of Initial Dose, Maintenance Dose and Annual Treatment Cost of Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (US$), March’2021

Figure 9-29: Kanjinti – Price for 150mg and 420mg Powder for Injection (US$), March’2021

Figure 9-30: Kanjinti – Initial and Maintenance Dose for Breast Cancer (mg/kg/Week), March’2021

Figure 9-31: Kanjinti – Average Cost of Initial Week, Maintenance Week and Annual Treatment of Breast Cancer (US$), March’2021

Figure 9-32: Kanjinti – Initial and Maintenance Dose for of Adjuvant Breast Cancer, Gastric Cancer and Esophageal Carcinoma (mg/kg/Week), March’2021

Figure 9-33: Kanjinti – Average Cost of Initial Week, Maintenance Week and Annual Treatment of Adjuvant Breast Cancer, Gastric Cancer and Esophageal Carcinoma (US$), March’2021

Figure 9-34: Herceptin Hylecta – Price for 5ml and Price Per ml of Subcutaneous Solution for Injection (US$), March’2021

Figure 9-35: Herceptin Hylecta – Duration of Single Treatment Cycle and Full Treatment (week), March’2021

Figure 9-36: Perjeta - Approval Year by Cancer Type

Figure 9-37: Perjeta – Patent Expiration Year by Region

Figure 9-38: Perjeta – Price for a Supply of 10 ml and Price Per ml of Intravenous Solution (US$), March’2021

Figure 9-39: Perjeta – Initial and Maintenance Dose for Breast Cancer Treatment (mg/3 weeks), March’2021

Figure 9-40: Perjeta – Minimum and Maximum Treatment Cost for Breast Cancer (US$), March’2021

Figure 9-41: Perjeta – Minimum and Maximum Treatment Cost of Neoadjuvant Breast Cancer Treatment (US$), March’2021

Figure 9-42: US - Perjeta Annual Sales Value (US$/CHF Million), 2017 - 2020

Figure 9-43: US - Perjeta Quarterly Sales Value (US$ Billion), 2019

Figure 9-44: US - Perjeta Quarterly Sales Value (US$ Million), 2020

Figure 10-1: Avastin – FDA Approval Year by Indication

Figure 10-2: Avastin – Price for a Supply of 10 and Price for Single 4ml Solution for Injection (US$), March’2021

Figure 10-3: Avastin – Price for a Supply of 10 and Price for Single 16ml Solution for Injection (US$), March’2021

Figure 10-4: Avastin – Pice for Single Treatment Cycle and Annual Treatment of Breast Cancer (US$), March’2021

Figure 10-5: Avastin – Cost of Single Treatment Cycle and Annual Treatment Cost for NSCLC and Metastatic Cervical Cancer (US$), March’2021

Figure 10-6: Avastin – Cost of Single Treatment Cycle and Annual Treatment Cost for Recurrent Glioblastoma and Renal Cell Carcinoma (US$), March’2021

Figure 10-7: Avastin – Duration of Treatment of Recurrent Glioblastoma and Renal Cell Carcinoma as Combinational and Monotherapy (Weeks), March’2021

Figure 10-8: Avastin – Cost of Single Treatment Cycle and Annual Treatment Cost for Recurrent Glioblastoma and Renal Cell Carcinoma (US$), March’2021

Figure 10-9: US - Avastin Annual Sales Value (US$/CHF Billion), 2017 - 2020

Figure 10-10: US - Avastin Quarterly Sales Value (US$ Billion), 2019

Figure 10-11: US - Avastin Quarterly Sales Value (US$ Million), 2020

Figure 10-12: Mvasi - Price for 4ml Supply and Price Per ml of Intravenous Solution (US$), March’2021

Figure 10-13: Mvasi - Price for 16 ml Supply and Price Per Unit of Intravenous Solution (US$), March’2021

Figure 10-14: Mvasi – Cost of Single Treatment Cycle and Annual Treatment Cost for NSCLC and Metastatic Cervical Cancer (US$), March’2021

Figure 10-15: Mvasi – Cost of Single Treatment Cycle and Annual Treatment Cost for Recurrent Glioblastoma and Renal Cell Carcinoma (US$), March’2021

Figure 10-16: Global - Mvasi Annual Sales Value (US$ Million), 2019 and 2020

Figure 10-17: US - Mvasi Annual Sales Value (US$ Million), 2019 and 2020

Figure 10-18: Global - Mvasi Quarterly Sales Value (US$ Million), 2020

Figure 10-19: US - Mvasi Quarterly Sales Value (US$ Million), 2020

Figure 10-20: Zirabev - Price for 4ml Supply and Price Per Unit of Intravenous Solution (US$), March’2021

Figure 10-21: Zirabev - Price for 16 ml Supply and Price Per Unit of Intravenous Solution (US$), March’2021

Figure 10-22: Zirabev – Cost of Single Treatment Cycle and Annual Treatment Cost for NSCLC and Metastatic Cervical Cancer (US$), March’2021

Figure 10-23: Zirabev – Cost of Single Treatment Cycle and Annual Treatment Cost for Recurrent Glioblastoma and Renal Cell Carcinoma (US$), March’2021

Figure 10-24: US – Ramucirumab FDA Approval Year by Indication

Figure 10-25: US - Ramucirumab Patent Approval and Expiration Year

Figure 10-26: Cyramza – Cost of Supply of 10ml and Per Unit Cost of Intravenous Solution (US$), March’2021

Figure 10-27: Cyramza – Cost of Supply of 50ml and Per Unit Cost of Intravenous Solution (US$), March’2021

Figure 10-28: Cyramza – Cost of Single Cycle and Annual Treatment Cost for NSCLC (US$)

Figure 10-29: Cyramza – Cost of Single Cycle and Annual Treatment Cost for Gastric, Colorectal and Hepatocellular Carcinoma (US$)

Figure 10-30: Global – Cyramza Annual Sales (US$ Million), 2017-2020

Figure 10-31: US – Cyramza Annual Sales (US$ Million), 2017-2020

Figure 10-32: Cyramza – Annual Sales by Region (US$ Million), 2017-2020

Figure 10-33: Global - Cyramza Annual Sales Value by Region (%), 2020

Figure 10-34: Global – Cyramza Quarterly Sales (US$ Million), 2019 and 2020

Figure 11-1: Kadcyla – FDA Approval Year for Late Stage and Early Stage HER2+ Breast Cancer

Figure 11-2; Kadcyla – Price for Single Unit of 100mg and 160mg Intravenous Powder for Injection (US$), March’2021

Figure 11-3: Kadcyla - Duration of Single Treatment Cycle and Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)

Figure 11-4: Kadcyla – Average Cost of Single Treatment Cycle and Full Treatment of Early Stage HER2 Breast Cancer in Human with Average Weight (US$), March’2021

Figure 11-5: Kadcyla – Recommended Dose After 1st and 2nd Dose Reduction (mg/m2)

Figure 11-6: US - Kadcyla Annual Sales Value (US$/CHF Million), 2017 - 2020

Figure 11-7: US - Kadcyla Quarterly Sales Value (US$ Billion), 2019

Figure 11-8: US - Kadcyla Quarterly Sales Value (US$ Million), 2020

Figure 11-9: Enhertu – FDA Approval Year for Late Stage and Early Stage HER2+ Breast Cancer

Figure 11-10: Enhertu – Cost of Single Supply and Single Treatment Cycle (US$), March’2021

Figure 11-11: Enhertu – Recommended Initial and Reduced Dose (mg/Kg/Cycle), March’2021

Figure 11-12: Enhertu – Cost of Single Treatment Cycle and Annual Treatment of Gastric Cancer (US$), March’2021

Figure 11-13: US - Enhertu Quarterly Sales Value (US$ Million), 2020

Figure 11-14: Trodelvy – FDA Approval and Patent Expiration Year

Figure 11-15: Trodelvy – Average Cost of Single Treatment Cycle and Full Treatment, March’2021

Figure 11-16: US - Trodelvy Quarterly Sales Value (US$ Million), Q2 – Q4, 2020

Figure 11-17: Lumoxiti – Year of Orphan Designation, FDA Approval and Patent Expiration

Figure 11-18: Lumoxiti – Duration of Single Treatment Cycle and Full Treatment (Weeks)

Figure 11-19: Lumoxitin – Cost of Single Dose, Single Treatment Cycle and Full Treatment of Hairy Cell Leukemia (US$), March’2021

Figure 11-20: Besponsa – Duration of Initial Treatment Cycle and Subsequent Cycles (Days)

Figure 11-21; Besponsa – Recommended Dose for 1st, 8th and 15th Day of Initial Treatment Cycle (mg/m2)

Figure 11-22: Besponsa – Cost of Single Unit and Full Cost of Initial Treatment Cycle (US$), March’2021

Figure 11-23: Besponsa – Cost of Single Unit and Full Cost of Subsequent Treatment Cycle in Patient with CR (US$), March’2021

Figure 11-24: Besponsa – Duration of Treatment of ALL – After and Without HSCT (Weeks)

Figure 11-25: Mylotarg – FDA Approval, Withdrawal and Re-Approval Year

Figure 11-26: Mylotarg – Number of Induction Cycle and Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML

Figure 11-27: Mylotarg – Cost of Induction Cycle, Consolidation Cycles and Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US$), March’2021

Figure 11-28: Mylotarg – Recommended Number of Induction and Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML

Figure 11-29: Mylotarg – Length of Induction and Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days)

Figure 11-30: Mylotarg – Recommended Dose of Initial Dose and Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m2)

Figure 11-31: Mylotarg – Cost of Induction Phase and Continuation Phase and Full Treatment Cost of CD-33 positive AML (US$), March’2021

Figure 11-32: Mylotarg – Cost of Single Dose and Full Treatment Cost of Relapsed and Refractory CD33 Positive AML, March’2021

Figure 11-33: Blenrep – Price for 100mg Supply and Price for Single Treatment Cycle (US$), March’2021

Figure 11-34: US - Blenrep Quarter Sales Value (US$/GBP Million), Q3 and Q4, 2020

Figure 11-35: Global - Blenrep Annual Sales Value by Region (US$/GBP Million), 2020

Figure 11-36: Blenrep - US v/s Rest of World Share in Sales Value (%), 2020

Figure 11-37: Adcetris – Patent Issue and Expiration Year

Figure 11-38: Adcetris – Maximum Cost for Treatment of Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US$), March’2021

Figure 11-39: Adcetris – Duration for Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (Weeks)

Figure 11-40: Global - Adcetris Sales Value (US$ Million), 2017 - 2020

Figure 11-41: Polivy – Patent Issue and Expiration Year

Figure 11-42: Polivy – Price for 30mg and 140mg Intravenous Powder for Injection (US$), March’2021

Figure 11-43: Polivy - Duration of Single Treatment Cycle and Full Treatment (Weeks), March’2021

Figure 11-44: Polivy – Cost of Single Dose, Single Treatment Cycle and Full Treatment of Hairy Cell Leukemia (US$), March’2021

Figure 11-45: US - Polivy Annual Sales Value (US$/CHF Million), 2019 and 2020

Figure 11-46: US - Polivy Quarter Sales Value (US$/CHF Million), Q3 and Q4, 2019

Figure 11-47: US - Polivy Quarter Sales Value (US$/CHF Million), 2020

Figure 11-48: Polivy - US v/s Rest of World Share in Sales Value (%), 2020

Figure 11-49: Padcev – Price for 20mg and 30mg Intravenous Powder for Injection (US$), March’2021

Figure 11-50: Padcev – Average Cost of Single Dose, Single Treatment Cycle and Full Treatment (US$), March’2021

Figure 11-51: US - Padcev Annual Sales Value (US$ Million), 2019 - 2020

Figure 11-52: US - Padcev Quarterly Sales Value (US$ Million), 2020

Figure 12-1: Rituxan – FDA Approval Year by Indication

Figure 12-2: Rituxan – Price for a Supply of 10 ml and Price Per ml of Solution for Injection (US$), March’2021

Figure 12-3: Rituxan – Price for a Supply of 50 ml and Price Per ml of Solution for Injection (US$), March’2021

Figure 12-4: Rituxan – Price for a Supply of 100 ml and Price Per ml of Solution for Injection (US$), March’2021

Figure 12-5: Rituxan – Average Minimum and Maximum Cost for Refractory CD20+ B-Cell NHL Management (US$), March’2021

Figure 12-6: Rituxan – Average Cost for Single Dose and Cost of Full Maintenance Phase for CLL (US$), March’2021

Figure 12-7: US - Rituxan Annual Sales Value (US$/CHF Billion), 2017 - 2020

Figure 12-8: US - Rituxan Quarterly Sales Value (US$ Billion), 2019

Figure 12-9: US - Rituxan Quarterly Sales Value (US$ Million), 2020

Figure 12-10: Rituxan – Annual Sales Value by Region (%), 2020

Figure 12-11: Truxima – Price for a Supply of 10 ml and Price Per ml of Solution for Injection (US$), March’2021

Figure 12-12: Truxima – Price for a Supply of 50 ml and Price Per ml of Solution for Injection (US$), March’2021

Figure 12-13: Truxima – Average Minimum and Maximum Cost for Refractory CD20+ B-Cell NHL Management (US$), March’2021

Figure 12-14: Truxima – Average Cost for Single Dose and Cost of Full Maintenance Phase for CLL (US$), March’2021

Figure 12-15: Riabni – Cost of Supply of 10ml and Per Unit Price of 10mg/ml Intravenous Solution (US$), March’2021

Figure 12-16: Riabni – Cost of Supply of 50ml and Per Unit Price of 10mg/ml Intravenous Solution (US$), March’2021

Figure 12-17: Riabni – Cost of 8 Cycles, 4 Cycles and Single Cycle for Management of NHL (US$)

Figure 12-18: Ruxience – Cost of Supply of 10ml and Per Unit Price of 10mg/ml Intravenous Solution (US$), March’2021

Figure 12-19: Ruxience – Cost of Supply of 50ml and Per Unit Price of 10mg/ml Intravenous Solution (US$), March’2021

Figure 12-20: Ruxience – Cost of 8 Cycles, 4 Cycles and Single Cycle for Management of NHL (US$)

Figure 12-21: Rituxan Hycela – Price for 11.7 ml Supply and Price Per ml of 23,400 units-1,400mg/11.7 ml Subcutaneous Solution (US$), March’2021

Figure 12-22: Rituxan Hycela – Price for 13.4 ml Supply and Price Per ml of 26,800 units–1,600 mg/13.4ml Subcutaneous Solution (US$), March’2021

Figure 12-23: Rituxan Hycela –Minimum and Maximum Duration of Follicular lymphoma Treatment (Weeks)

Figure 12-24: Rituxan Hycela – Average Minimum and Maximum Cost of Follicular lymphoma (US$), March’2021

Figure 12-25: Rituxan Hycela – Duration of Single Treatment Cycle and Full Treatment of Previously Untreated Follicular lymphoma (US$)

Figure 12-26: Rituxan Hycela – Average Minimum and Maximum Cost of Previously Untreated Follicular lymphoma (US$), March’2021

Figure 12-27: Rituxan Hycela – Average Minimum and Maximum Cost of Diffuse Large B-Cell Lymphoma (US$), March’2021

Figure 12-28: Rituxan Hycela – Duration of CLL Treatment (Weeks)

Figure 12-29: Rituxan Hycela - Cost of Single Treatment Cycle and Full Treatment of CLL (US$), March’2021

Figure 12-30: Gazyva – Approval Year by Cancer Type

Figure 12-31: Gazyva – Price for 40ml Supply and Price Per ml of Intravenous Solution (US$), March’2021

Figure 12-32: Gazyva – Recommended Dosing Schedule for Initial Treatment Cycle of CLL (mg), March’2021

Figure 12-33: Gazyva – Duration of Single Treatment Cycle and Full Treatment of CLL (Week), March’2021

Figure 12-34: Gazyva – Cost of Initial and Subsequent Treatment Cycle and Full Treatment Cost of CLL (US$), March’2021

Figure 12-35: Gazyva – Minimum and Maximum Duration for Follicular Lymphoma Treatment (Week), March’2021

Figure 12-36: Gazyva – Minimum and Maximum Treatment Cost of Follicular Lymphoma (US$), March’2021

Figure 12-37: Gazyva – Duration of Single Treatment Cycle and Full Treatment Using Monotherapy (Months), March’2021

Figure 12-38: Gazyva – Cost of Single Treatment Cycle and Full Treatment using Monotherapy (US$), March’2021

Figure 12-39: Gazyva – Annual Sales Value (US$/CHF Million), 2017 - 2020

Figure 12-40: US - Gazyva Quarterly Sales Value (US$/CHF Million), 2019

Figure 12-41: Gazyva - US v/s Rest of World Share in Sales Value (%), 2019

Figure 12-42: US - Gazyva Quarterly Sales Value (US$/CHF Million), 2020

Figure 12-43: Gazyva - US v/s Rest of World Share in Sales Value (%), 2020

Figure 12-44: Arzerra – Price for a Supply of 15 ml, 5 ml and Price per ml of Intravenous Solution (US$), March’2021

Figure 12-45: Arzerra – Price for a Supply of 50 ml and Price Per ml of Intravenous Solution (US$), March’2021

Figure 12-46: Arzerra – Initial and Maintenance Dose for Previously Untreated CLL (mg), March’2021

Figure 12-47: Arzerra – Minimum and Maximum Treatment Duration for Previously Untreated CLL (Weeks), March’2021

Figure 12-48: Arzerra – Minimum and Maximum Treatment Cost for Previously Untreated CLL (US$), March’2021

Figure 12-49: Arzerra – Initial and Maintenance Dose for Relapsed CLL (mg), March’2021

Figure 12-50: Arzerra – Minimum and Maximum Treatment Cost for Relapsed CLL (US$), March’2021

Figure 12-51: Arzerra – Initial and Maintenance Dose for Refractory CLL (mg), March’2021

Figure 12-52: Arzerra – Treatment Duration for Refractory CLL (Weeks), March’2021

Figure 12-53: Arzerra – Minimum and Maximum Treatment Cost for Refractory CLL (US$), March’2021

Figure 13-1: Blincyto - Number of Induction and Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, March’2021

Figure 13-2: Blincyto - Duration of Treatment Phase and Resting Phase in Induction and Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days) , March’2021

Figure 13-3: Blincyto - Cost of Single Cycle and Full Treatment Cost of MRD+ B-cell precursor ALL (US$), March’2021

Figure 13-4: Blincyto - Recommended Number of Induction and Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, March’2021

Figure 13-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle and Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), March’2021

Figure 13-6: Blincyto - Cost of 1st and 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), March’2021

Figure 13-7: Blincyto - Cost of Different Treatment Phases for Relapsed B-Cell Precursor ALL (US$), March’2021

Figure 13-8: US - Blincyto Sales Value (US$ Million), 2016 - 2020

Figure 13-9: Blincyto - Quarterly Sales Value (US$ Million), 2019

Figure 13-10: Blincyto - US v/s Rest of World Share in Sales Value (%), 2019

Figure 13-11: US - Blincyto Quarterly Sales Value (US$ Million), 2020

Figure 13-12: Blincyto - US v/s Rest of World Share in Sales Value (%), 2020

Figure 14-1: Lemtrada – Price for 1.2ml Supply and Price Per ml of Intravenous Solution (US$), March’2021

Figure 14-2: Lemtrada – Cost of Single Dose and Single Treatment Cycle (US$), March’2021

Figure 14-3: US - Lemtrada Annual Sales Value (US$/EUR Million), 2018 - 2020

Figure 14-4: US - Lemtrada Quarterly Sales Value (US$/EUR Million), 2020

Figure 14-5: Lemtrada - US v/s Rest of World Share in Sales Value (%), 2020

Figure 15-1: Sarclisa – FDA Approval and Patent Expiration Year

Figure 15-2: Sarclisa – Price for 5 ml Supply and Price Per ml of 20mg/ml Intravenous Solution (US$), March’2021

Figure 15-3: Sarclisa – Price for 25 ml Supply and Price Per ml of 20mg/ml Intravenous Solution (US$), March’2021

Figure 15-4: Sarclisa – Number of Dose Required in Initial and Subsequent Treatment Cycles (Weeks)

Figure 15-5: US - Sarclisa Quarter Sales Value (US$/EUR Million), 2020

Figure 15-6: Global - Sarclisa Annual Sales Value by Region (US$/EUR Million), 2020

Figure 15-7: Sarclisa - US v/s Rest of World Share in Sales Value (%), 2020

Figure 15-8: Darzalex – FDA Approval and Patent Expiration Year

Figure 15-9: Darzalex – Price for 5 ml Supply and Price Per ml of 20mg/ml Intravenous Solution (US$), March’2021

Figure 15-10: Darzalex – Price for 20 ml Supply and Price Per ml of 20mg/ml Intravenous Solution (US$), March’2021

Figure 15-11: Darzalex – Duration of Dose Interval by Treatment Phase (Weeks)

Figure 15-12: US - Darzalex Annual Sales Value (US$ Million), 2017 - 2020

Figure 15-13: Darzalex – Annual Sales by Region (%), 2019

Figure 15-14: US - Darzalex Quarterly Sales Value (US$ Million), 2019

Figure 15-15: US - Darzalex Quarterly Sales Value (US$ Million), 2020

Figure 15-16: Darzalex – Annual Sales by Region (%), 2020

Figure 15-17: Darzalex Faspro – FDA Approval and Patent Expiration Year

Figure 15-18: Darzalex Faspro – Price for 15 ml Supply and Price Per ml of Subcutaneous Solution (US$), March’2021

Figure 15-19: Darzalex Faspro – Duration of Dose Interval by Treatment Phase (Weeks)

Figure 16-1: Keytruda – Patent Expiration Year by Region

Figure 16-2: Keytruda – Price for 4ml and 8ml Supply and Price Per ml of Intravenous Injection (US$), March’2021

Figure 16-3: Keytruda – Duration of Single Treatment Cycle and Full Treatment of Melanoma and Other Cancers (Weeks), March’2021

Figure 16-4: Keytruda - Cost of Single and Full Treatment using Solution of Injection (US$), March’2021

Figure 16-5: Global - Keytruda Annual Sales Value by Region (US$ Billion), 2020

Figure 16-6: Global - Keytruda Annual Sales Value by Region (%), 2020

Figure 16-7: US - Keytruda Annual Sales Value (US$ Billion), 2017 - 2020

Figure 16-8: US - Keytruda Quarterly Sales Value (US$ Million), 2018 and 2019

Figure 16-9: US - Keytruda Quarterly Sales Value (US$ Million), 2020

Figure 16-10: Yervoy – US and Europe Exclusivity Expiration Year

Figure 16-11: Yervoy - Price for 10ml Supply and Price Per ml 5mg/ml Intravenous Injection (US$), March’2021

Figure 16-12: Yervoy – Price for 40ml Supply and Price Per ml 5mg/ml Intravenous Injection (US$), March’2021

Figure 16-13: Yervoy – Duration of Single Treatment Cycle and Full Treatment of Metastatic Melanoma and Hepatocellular Carcinoma (Weeks), March’2021

Figure 16-14: Yervoy – Average Cost of Single Treatment Cycle and Full Treatment of Metastatic Melanoma and Hepatocellular Carcinoma (US$), March’2021

Figure 16-15: Yervoy – Average Cost of Single Treatment Cycle, Initial Year and Remaining Years for Management of Metastatic Melanoma (US$), March’2021

Figure 16-16: Yervoy – Annual Sales Value (US$ Billion), 2016-2020

Figure 16-17: Global - Yervoy Quarterly Sales Value (US$ Million), 2018 and 2019

Figure 16-18: US - Yervoy Quarterly Sales Value (US$ Million), Q1-Q4, 2019

Figure 16-19: Yervoy – US v/s Rest of World Sales Share (%), 2019

Figure 16-20: Global - Yervoy Quarterly Sales Value (US$ Million), Q1-Q4, 2020

Figure 16-21: US - Yervoy Quarterly Sales Value (US$ Million), Q1-Q4, 2020

Figure 16-22: Yervoy – Annual Sales by Region (%), 2020

Figure 16-23: Opdivo – FDA Approval by Indication

Figure 16-24: Opdivo - Patent Expiration Year by Region

Figure 16-25: Opdivo - Price for 4ml Supply and Price Per ml of 10mg/ml Intravenous Injection (US$), March’2021

Figure 16-26: Opdivo - Price for 10 ml Supply and Price Per ml of 10mg/ml Intravenous Injection (US$), March’2021

Figure 16-27: Opdivo - Price for 20 ml Supply and Price Per ml of 10mg/ml Intravenous Injection (US$), March’2021

Figure 16-28: Opdivo Monotherapy Therapy - Single Treatment Cycle and Full Treatment Average Cost (US$), March’2021

Figure 16-29: US - Opdivo Annual Sales Value (US$ Million), 2016 - 2020

Figure 16-30: Opdivo – Annual Sales by Region (%), 2019

Figure 16-31: US - Opdivo Quarterly Sales Value (US$ Billion), 2018 and 2019

Figure 16-32: US - Opdivo Quarterly Sales Value (US$ Million), 2020

Figure 16-33: Imfinzi – FDA Approval Year by Indication

Figure 16-34: Imfinzi – FDA Approval and Patent Expiration Year

Figure 16-35: Imfinzi – Price for a Supply of 2.4ml and Price Per ml of Solution for Injection (US$), March’2021

Figure 16-36: Imfinzi – Price for a Supply of 10 ml and Price Per ml of Solution for Injection (US$), March’2021

Figure 16-37: Imfinzi - Average Cost of Single Treatment Cycle and Full Treatment of NSCLC (US$), March’2021

Figure 16-38: Global - Imfinzi Annual Sales Value (US$ Million), 2017 - 2020

Figure 16-39: US - Imfinzi Annual Sales Value (US$ Million), 2017 - 2020

Figure 16-40: Imfinzi - Quarterly Sales Value by Region (US$ Million), 2018 and 2019

Figure 16-41: Global - Imfinzi Quarterly Sales Value (US$ Million), 2020

Figure 16-42: US - Imfinzi Quarterly Sales Value US$ Million), 2020

Figure 16-43: Imfinzi – Annual Sales by Region (%), 2020

Figure 16-44: Bavencio – FDA Approval Year by Indication

Figure 16-45: Bavencio - Price for 10ml Supply and Price Per ml of 20mg/ml Intravenous Injection (US$), March’2021

Figure 16-46: Bavencio - Average Cost of Single Treatment Cycle and Annual Treatment (US$), March’2021

Figure 16-47: Bavencio – Annual Sales Value (US$/EUR Million), 2017-2019

Figure 16-48: Bavencio – Quarterly Sales Value (US$ Million), Q1-Q3, 2019 and 2020

andlt;spa

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

US Cancer Antibody Market, Drug Price, Sales and Clinical Trials Insight 2026

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Click Here: US Cancer Antibodies Market, Drug Sales, Patent and Clinical Trials Outlook 2028

"US Cancer Antibody Market, Drug Price, Sales and Clinical Trials Insight 2026" Report Highlights:

US Cancer Antibodies Market Opportunity: > US$ 70 Billion by 2026

US Cancer Antibodies Market Growth: 100% Absolute Growth Till 2026

US Cancer Antibodies Market Size Opportunity by Therapeutic Class

Insight On Clinical Trials by Company, Indication, Patient Segment and Phase

Insight on FDA Approved 57 Cancer Antibodies Available in US Market

Price, Dosage, Patent and Sales Insight on Cancer Antibodies Available In Market

US Cancer Biosimilar Market Opportunity Insight: > US$ 10 Billion by 2026

US Cancer Antibodies Market Analysis

1.1 Overview

1.2 Current Market Scenario

1.3 US - Leading Cancer Antibodies

US Cancer Antibodies Market Segmentation by Therapeutic Class

2.1 Immune Checkpoint Inhibitors

2.2 US Bispecific Antibody Market

2.3 US Antibody Drug Conjugate Market

2.4 Other Cancer Antibody Therapeutics

2.4.1 VEGF/VEGFR Inhibiting Antibodies

2.4.2 CD20 Targeting Antibodies

2.4.3 CD38 Targeting Antibodies

2.4.4 EGFR Inhibiting Antibodies

US Breast Cancer Antibodies Market

3.1 Current Market Scenario

3.2 Leading Breast Cancer Antibodies

US Blood Cancer Antibody Market

4.1 Current Market Scenario

4.2 Leading Blood Cancer Targeting Antibodies

US Lung Cancer Antibody Market

5.1 Current Market Scenario

5.2 Leading Antibodies for Lung Cancer

US Colorectal Cancer Antibodies Market Overview

US Cancer Biosimilar Market

7.1 Current Market Scenario

7.2 Market Opportunity and Future Forecast

Global Peptide Cancer Therapeutics Clinical Trials Overview

8.1 By Company

8.2 By Indication

8.3 By Patient Segment

8.4 By Phase

US HER2 Inhibiting Antibodies - Availability, Dosage, Patent, Price and Sales Analysis

9.1 Trastuzumab (Herceptin)

9.2 Trastuzumab Biosimilar (Ontruzant)

9.3 Trastuzumab Biosimilar (Ogivri)

9.4 Trastuzumab Biosimilar (Herzuma)

9.5 Trastuzumab Biosimilar (Trazimera)

9.6 Trastuzumab Biosimilar (Kanjinti)

9.7 Trastuzumab and Hyaluronidase Injection (Herceptin Hylecta)

9.8 Pertuzumab (Perjeta)

9.9 Margetuximab (Margenza)

US VEGF/VEGFR Inhibiting Antibodies -Availability, Dosage, Patent, Price and Sales Analysis

10.1 Bevacizumab (Avastin)

10.2 Bevacizumab Biosimilar (Mvasi)

10.3 Bevacizumab Biosimilar (Zirabev)

10.4 Ramucirumab (Cyramza)

US Antibody-Drug Conjugates - Availability, Dosage, Patent, Price and Sales Analysis

11.1 Ado-Trastuzumab Emtansine (Kadcyla)

11.2 Fam-Trastuzumab Deruxtecan (Enhertu)

11.3 Trodelvy (Sacituzumab Govitecan-hziy)

11.4 Moxetumomab Pasudotox-tdfk (Lumoxiti)

11.5 Inotuzumab Ozogamicin (Besponsa)

11.6 Gemtuzumab Ozogamicin (Mylotarg)

11.7 Belantamab Mafodotin-blmf (Blenrep)

11.8 Brentuximab Vedotin (Adcetris)

11.9 Polatuzumab Vedotin-piiq (Polivy)

11.10 Enfortumab Vedotin (Padcev)

US CD20-Directed Antibody - Availability, Dosage, Patent, Price and Sales Analysis

12.1 Rituximab (Mabthera/Rituxan)

12.2 Rituximab Biosimilar (Truxima)

12.3 Rituximab Biosimilar (Riabni)

12.4 Rituximab Biosimilar (Ruxience)

12.5 Rituximab/Hyaluronidase (Rituxan Hycela)

12.6 Obinutuzumab (Gazyva)

12.7 Ofatumumab (Arzerra)

US Bispecific Antibodies - Availability, Dosage, Patent, Price and Sales Analysis

13.1 Blinatumomab (Blincyto)

CD52 Monoclonal Antibodies - Availability, Dosage, Patent, Price and Sales Analysis

14.1 Alemtuzumab (Lemtrada)